BioLife Solutions (BLFS) Financials
Newest figures come from the 10-Q for Q2 FY2026, filed Aug 6, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the BLFS SEC filings page.
BioLife Solutions Inc. (BLFS) reported $96.2M in revenue for fiscal year 2025, up 28.9% from the prior fiscal year. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 15 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Sales expansion is improving cash generation, but operating costs still outrun gross profit, leaving a growing business unprofitable.
In FY2025, operating cash flow reached$20.1M while net loss was$4.6M and free cash flow was$10.6M , so reported earnings and cash production moved in opposite directions. Capital expenditures represented47.1% of operating cash flow, indicating that positive cash generation was not simply the result of minimal reinvestment.
Revenue rose
Long-term debt was
Financial Health Signals
Scored against emerging companies for FY2025. Each of the six dimensions is a percentile rank within that peer group, and the overall is the average of the dimensions that can be computed. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →
Health score ≠ stock price. This rates the quality of BioLife Solutions Inc.'s business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
BioLife Solutions Inc. held $88.9M in cash, cash equivalents and investments at the end of fiscal year 2025, and its operations generated $20.1M of cash that year. Cash Runway ranks emerging companies on the size of that balance against the outflow behind it, and BioLife Solutions Inc. scores 87/100 among other emerging companies.
BioLife Solutions Inc. had 48M shares outstanding at the end of fiscal year 2025, against 47M in fiscal year 2024. Dilution ranks emerging companies on how fast that count has grown over three years, where a slower rise is the better one, and BioLife Solutions Inc. scores 62/100 among other emerging companies.
BioLife Solutions Inc. spent $7.6M on research and development in fiscal year 2025, which was 6.7% of its operating costs that year. R&D Intensity ranks emerging companies on the share of operating costs that goes into research, and BioLife Solutions Inc. scores 29/100 among other emerging companies.
BioLife Solutions Inc. reported revenue of $96.2M in fiscal year 2025, against $74.6M in fiscal year 2024. Revenue Progress ranks emerging companies on the three-year path of that line, and BioLife Solutions Inc. scores 63/100 among other emerging companies.
BioLife Solutions Inc.'s operations generated $20.1M of cash in fiscal year 2025, against $8.4M generated in fiscal year 2024. Burn Trend ranks emerging companies on which way that figure has moved over three years, and BioLife Solutions Inc. scores 97/100 among other emerging companies.
BioLife Solutions Inc.'s cash, cash equivalents and investments came to $88.9M at the end of fiscal year 2025, against $34.0M of total liabilities. Balance Sheet ranks emerging companies on that comparison, and BioLife Solutions Inc. scores 79/100 among other emerging companies.
BioLife Solutions Inc. scores 32.60, well above the 2.99 safe threshold. The largest contribution to the score comes from a market capitalization of $1.9B against total liabilities of $34.0M. This indicates low bankruptcy risk based on profitability, leverage, and asset efficiency.
Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.
BioLife Solutions Inc. passes 6 of 9 financial strength tests. 3 of 4 profitability signals pass, 2 of 3 leverage/liquidity signals pass, 1 of 2 operating efficiency signals passes.
BioLife Solutions Inc. reported a net loss of $4.6M while generating $20.1M in operating cash flow. Operations generated cash despite the loss, but with no positive earnings behind it, the ratio between the two carries no quality signal.
Key Financial Metrics
Earnings & Revenue
BioLife Solutions Inc. generated $28.5M in revenue in Q2 2026. This represents an increase of 21.5% from the same quarter a year earlier. Against the prior quarter it is up 3.5%.
BioLife Solutions Inc.'s EBITDA was $2.3M in Q2 2026, measuring earnings before interest, taxes, depreciation, and amortization. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. Against the prior quarter it is up 461.8%.
BioLife Solutions Inc. reported $45.1M in net income in Q2 2026. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. Against the prior quarter it is up 3703.0%.
BioLife Solutions Inc. earned $0.91 per diluted share (EPS) in Q2 2026. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. Against the prior quarter it is up 4450.0%.
Cash & Balance Sheet
BioLife Solutions Inc. generated $5.3M in free cash flow in Q2 2026, representing cash available after capex. This represents a decrease of 5.7% from the same quarter a year earlier. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.
BioLife Solutions Inc. held $24.0M in cash against $0 in long-term debt as of Q2 2026.
Not reported for Q2 2026.
Margins & Returns
BioLife Solutions Inc.'s gross margin was 64.2% in Q2 2026, indicating the percentage of revenue retained after direct costs. This is down 0.8 percentage points from the same quarter a year earlier. Against the prior quarter it is up 0.6 percentage points.
BioLife Solutions Inc.'s operating margin was 6.0% in Q2 2026, reflecting core business profitability. This is up 74.8 percentage points from the same quarter a year earlier. Against the prior quarter it is up 5.9 percentage points.
BioLife Solutions Inc.'s quarterly ROE was 10.7% in Q2 2026: one quarter's net income over shareholder equity, not annualized. This is up 15.3 percentage points from the same quarter a year earlier. Against the prior quarter it is up 10.4 percentage points.
Not shown for Q2 2026: the reported ratio is above 100.0% of revenue, so it does not read as a share of revenue.
Capital Allocation
BioLife Solutions Inc. invested $3.0M in research and development in Q2 2026. This represents an increase of 50.5% from the same quarter a year earlier. Against the prior quarter it is up 11.6%.
BioLife Solutions Inc. invested $1.0M in capex in Q2 2026, funding long-term assets and infrastructure. This represents a decrease of 40.2% from the same quarter a year earlier. Against the prior quarter it is up 524.6%.
Not reported for Q2 2026.
BLFS Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-K | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Revenue | $28.5M+21.5% | $27.5M+24.7% | $22.7M+50.0% | $28.1M+31.2% | $23.4M+18.9% | $22.1M+19.6% | $15.1M | $21.4M-9.3% |
| Cost of Revenue | $10.2M+24.1% | $10.0M+37.9% | N/A | N/A | $8.2M | $7.3M | N/A | N/A |
| Gross Profit | $18.3M+20.0% | $17.5M+18.2% | N/A | N/A | $15.2M | $14.8M | N/A | N/A |
| R&D Expenses | $3.0M+50.5% | $2.6M+84.2% | $1.5M+16.6% | $2.7M+43.1% | $2.0M-3.2% | $1.4M-30.7% | -$1.2M | $1.9M-49.4% |
| SG&A Expenses | $13.5M-2.4% | $14.7M+6.8% | $13.2M+0.1% | $14.6M+23.4% | $13.8M+17.0% | $13.8M+8.0% | $13.2M | $11.8M-24.6% |
| Operating Income | $1.7Mn/m | $27Kn/m | $112K-79.3% | -$89Kn/m | -$16.1Mn/m | -$499Kn/m | $542K | -$418Kn/m |
| EBITDA | $2.3Mn/m | $401K+119.1% | $518K-79.9% | $810K+74.2% | -$15.9Mn/m | $183Kn/m | $2.6M | $465Kn/m |
| Interest Expense | N/A | N/A | N/A | N/A | N/A | N/A | $71K | $230K-48.8% |
| Income Tax | -$42.4M-33711.9% | $62K+342.9% | -$173K-820.8% | $82Kn/m | $126K+12500.0% | $14K-17.6% | $24K | -$80K-169.6% |
| Net Income | $45.1Mn/m | $1.2Mn/m | $11.1M-11.1% | $621Kn/m | -$15.8Mn/m | -$448Kn/m | $12.5M | -$1.7Mn/m |
| EPS (Basic) | $0.92n/m | $0.02n/m | $0.24-11.1% | $0.01n/m | -$0.33n/m | -$0.01n/m | $0.27n/m | -$0.04n/m |
| EPS (Diluted) | $0.91n/m | $0.02n/m | $0.23-14.8% | $0.01n/m | -$0.33n/m | $0.00n/m | $0.27n/m | -$0.04n/m |
| Diluted Shares (Avg) | 49M+3.1% | 49M+1.8% | N/A | 49M+5.5% | 48M+3.9% | 48M+6.5% | N/A | 46M+6.0% |
BLFS Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-K | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $447.5M+15.6% | $400.9M+1.5% | $405.9M+1.6% | $392.1M+2.7% | $387.2M+3.3% | $395.1M-1.6% | $399.5M-3.2% | $381.7M-7.2% |
| Current Assets | $135.2M+7.8% | $133.2M+1.6% | $136.6M-8.2% | $126.6M+41.6% | $125.4M+42.2% | $131.1M+17.4% | $148.8M+23.3% | $89.4M-23.5% |
| Cash & Equivalents | $24.0M-24.8% | $22.8M-65.9% | $33.0M-63.9% | $29.5M+23.0% | $31.9M+44.9% | $66.9M+125.4% | $91.5M+228.1% | $24.0M+24.7% |
| Short-Term Investments | $58.4M+17.2% | $58.2M+168.9% | $55.9M+507.6% | $49.5M+384.5% | $49.9M+311.4% | $21.6M+38.9% | $9.2M-43.5% | $10.2M-53.1% |
| Inventory | $35.6M+28.5% | $32.8M+19.1% | $30.2M+3.9% | $27.8M-13.5% | $27.7M-14.8% | $27.6M-36.5% | $29.0M+6.8% | $32.2M-25.8% |
| Accounts Receivable | $10.7M+5.9% | $13.1M+42.4% | $8.0M-6.2% | $10.8M-39.5% | $10.1M-44.3% | $9.2M-50.6% | $8.5M+7.3% | $17.9M-27.0% |
| Long-Term Investments | $0n/m | $0n/m | $0n/m | $0-100.0% | $0-100.0% | $0-100.0% | $0-100.0% | $4.9M+322.5% |
| Goodwill | $208.6M-1.8% | $208.6M-1.8% | $208.6M0.0% | $212.3M-5.5% | $212.3M-5.5% | $212.3M-5.5% | $208.6M-1.8% | $224.7M0.0% |
| Total Liabilities | $27.5M-31.4% | $28.7M-32.6% | $34.0M-32.8% | $38.3M-31.8% | $40.1M-25.1% | $42.5M-37.7% | $50.6M-32.6% | $56.2M-29.0% |
| Current Liabilities | $13.9M-50.7% | $18.3M-34.2% | $23.0M-29.8% | $27.1M-15.6% | $28.3M-8.1% | $27.7M-28.3% | $32.7M-22.4% | $32.2M-24.5% |
| Non-Current Liabilities | $13.5M+15.0% | $10.4M-29.5% | $11.0M-38.3% | $11.2M-53.4% | $11.8M-48.2% | $14.8M-49.9% | $17.8M-45.7% | $24.0M-34.2% |
| Long-Term Debt | $0n/m | $2.5M0.0% | $0-100.0% | $0-100.0% | $0-100.0% | $2.5M-84.1% | $5.0M-71.5% | $7.8M-62.6% |
| Total Equity | $420.0M+21.0% | $372.2M+5.6% | $371.9M+6.6% | $353.7M+8.7% | $347.2M+8.0% | $352.6M+5.8% | $348.9M+3.3% | $325.5M-2.0% |
| Retained Earnings | -$293.4Mn/m | -$338.5Mn/m | -$339.7Mn/m | -$350.8Mn/m | -$351.4Mn/m | -$335.5Mn/m | -$335.1Mn/m | -$347.6Mn/m |
BLFS Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-K | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | $6.3M-13.8% | -$491K-128.4% | $4.9M+198.8% | $6.1M+27.1% | $7.4M+14.1% | $1.7Mn/m | $1.6M-28.8% | $4.8Mn/m |
| Depreciation & Amortization | $557K+109.4% | $374K-45.2% | $261K-72.1% | $899K+1.8% | $266K-69.9% | $682K-50.0% | $937K-36.2% | $883K-61.8% |
| Stock-Based Compensation | $3.9M-32.5% | $4.8M+15.7% | N/A | $5.9M+42.6% | $5.7M+43.7% | $4.2M-32.8% | N/A | $4.1M-48.2% |
| Capital Expenditures | $1.0M-40.2% | $167K-4.6% | N/A | N/A | $1.7M | $175K | N/A | N/A |
| Free Cash Flow | $5.3M-5.7% | -$658K-142.4% | N/A | N/A | $5.6M | $1.6M | N/A | N/A |
| Investing Cash Flow | -$1.6Mn/m | -$1.8Mn/m | $1.1M-98.5% | -$6.0Mn/m | -$39.5Mn/m | -$27.2Mn/m | $73.6M+1760.9% | -$1.7M-201.1% |
| Financing Cash Flow | -$3.6Mn/m | -$7.9Mn/m | -$2.5Mn/m | -$2.6Mn/m | -$2.9Mn/m | -$3.0Mn/m | -$4.1M-141.5% | -$1.0M-271.2% |
Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.
BLFS Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-K | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | 64.2%-0.8pp | 63.6%-3.5pp | N/A | N/A | 65.0% | 67.1% | N/A | N/A |
| Operating Margin | 6.0%+74.8pp | 0.1%+2.4pp | 0.5%-3.1pp | -0.3%+1.6pp | -68.8%-62.2pp | -2.3%+15.6pp | 3.6% | -1.9%+63.7pp |
| Net Margin | 158.4% | 4.3%+6.3pp | 48.9%-33.6pp | 2.2%+10.2pp | -67.6% | -2.0%+53.4pp | 82.5% | -8.0% |
| Return on Equity | 10.7%+15.3pp | 0.3%+0.5pp | 3.0%-0.6pp | 0.2%+0.7pp | -4.6%+1.9pp | -0.1%+2.9pp | 3.6% | -0.5%+8.3pp |
| Return on Assets | 10.1%+14.2pp | 0.3%+0.4pp | 2.7%-0.4pp | 0.2%+0.6pp | -4.1%+1.4pp | -0.1%+2.4pp | 3.1% | -0.4%+6.6pp |
| Current Ratio | 9.69+5.3x | 7.30+2.6x | 5.94+1.4x | 4.66+1.9x | 4.43+1.6x | 4.73+1.8x | 4.54+1.7x | 2.780.0x |
| Debt-to-Equity | 0.000.0x | 0.010.0x | 0.000.0x | 0.000.0x | 0.000.0x | 0.010.0x | 0.010.0x | 0.020.0x |
| Liabilities-to-Equity | 0.07-0.1x | 0.080.0x | 0.09-0.1x | 0.11-0.1x | 0.12-0.1x | 0.12-0.1x | 0.14-0.1x | 0.17-0.1x |
| Asset Turnover | 0.060.0x | 0.070.0x | 0.060.0x | 0.070.0x | 0.060.0x | 0.060.0x | 0.04 | 0.060.0x |
| FCF Margin | 18.6%-5.4pp | -2.4%-9.4pp | N/A | N/A | 24.0% | 7.0% | N/A | N/A |
Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Net Margin.
Similar Companies
Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.
| Company | Fiscal year | Revenue | Net income | Net margin | Market cap | Health score |
|---|---|---|---|---|---|---|
| BioLife Solutions Inc. BLFS | FY2025 | $96.2M | -$4.6M | -4.8% | $1.9B | 70/100 |
| Staar Surgical Co STAA | FY2025 | $239.4M | -$80.4M | -33.6% | $1.2B | 33/100 |
| Azenta, Inc. AZTA | FY2025 | $593.8M | -$55.8M | -9.4% | $1.8B | 49/100 |
| Kestra Medical Technologies, Ltd. KMTS | FY2026 | $95.1M | -$131.6M | N/A | $1.8B | 51/100 |
| Pulse Biosciences, Inc PLSE | FY2025 | $350K | -$72.8M | N/A | $3.8B | — |
| Embecta Corp. EMBC | FY2025 | $1.1B | $95.4M | 8.8% | $366.0M | 57/100 |
Where BioLife Solutions Inc. Ranks
Frequently Asked Questions
What is BioLife Solutions Inc.'s annual revenue?
BioLife Solutions Inc. (BLFS) reported $96.2M in total revenue for fiscal year 2025. This represents a 28.9% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is BioLife Solutions Inc.'s revenue growing?
BioLife Solutions Inc. (BLFS) revenue grew by 28.9% year-over-year, from $74.6M to $96.2M in fiscal year 2025.
Is BioLife Solutions Inc. profitable?
No, BioLife Solutions Inc. (BLFS) reported a net loss of $4.6M in fiscal year 2025, with a net profit margin of -4.8%.
What is BioLife Solutions Inc.'s EBITDA?
BioLife Solutions Inc. (BLFS) had EBITDA of -$14.3M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
How much debt does BioLife Solutions Inc. have?
As of fiscal year 2025, BioLife Solutions Inc. (BLFS) had $33.0M in cash and equivalents against $0 in long-term debt.
What is BioLife Solutions Inc.'s gross margin?
BioLife Solutions Inc. (BLFS) had a gross margin of 64.6% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.
What is BioLife Solutions Inc.'s operating margin?
BioLife Solutions Inc. (BLFS) had an operating margin of -17.3% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.
What is BioLife Solutions Inc.'s net profit margin?
BioLife Solutions Inc. (BLFS) had a net profit margin of -4.8% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.
What is BioLife Solutions Inc.'s return on equity (ROE)?
BioLife Solutions Inc. (BLFS) has a return on equity of -1.2% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is BioLife Solutions Inc.'s free cash flow?
BioLife Solutions Inc. (BLFS) generated $10.6M in free cash flow during fiscal year 2025. This represents a 104.4% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is BioLife Solutions Inc.'s operating cash flow?
BioLife Solutions Inc. (BLFS) generated $20.1M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.
What are BioLife Solutions Inc.'s total assets?
BioLife Solutions Inc. (BLFS) had $405.9M in total assets as of fiscal year 2025, including both current and long-term assets.
What are BioLife Solutions Inc.'s capital expenditures?
BioLife Solutions Inc. (BLFS) invested $9.5M in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
How much does BioLife Solutions Inc. spend on research and development?
BioLife Solutions Inc. (BLFS) invested $7.6M in research and development during fiscal year 2025.
What is BioLife Solutions Inc.'s current ratio?
BioLife Solutions Inc. (BLFS) had a current ratio of 5.94 as of fiscal year 2025, which is generally considered healthy.
What is BioLife Solutions Inc.'s debt-to-equity ratio?
BioLife Solutions Inc. (BLFS) had a debt-to-equity ratio of 0.00 as of fiscal year 2025. We compute it as long-term debt divided by total shareholder equity, where long-term debt is the noncurrent part of the company's borrowings, so debt due within the next twelve months is not counted.
What is BioLife Solutions Inc.'s liabilities-to-equity ratio?
BioLife Solutions Inc. (BLFS) had a liabilities-to-equity ratio of 0.09 as of fiscal year 2025, which is total liabilities divided by total shareholder equity. Total liabilities counts every obligation on the balance sheet (payables, deposits, insurance reserves and deferred taxes as well as borrowings), so this ratio usually runs well above debt-to-equity.
What is BioLife Solutions Inc.'s return on assets (ROA)?
BioLife Solutions Inc. (BLFS) had a return on assets of -1.1% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is BioLife Solutions Inc.'s Altman Z-Score?
BioLife Solutions Inc. (BLFS) has an Altman Z-Score of 32.60, placing it in the Safe Zone (low bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
What is BioLife Solutions Inc.'s Piotroski F-Score?
BioLife Solutions Inc. (BLFS) has a Piotroski F-Score of 6 out of 9, indicating neutral financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are BioLife Solutions Inc.'s earnings high quality?
BioLife Solutions Inc. (BLFS) reported a net loss of $4.6M while generating $20.1M in operating cash flow. Operations generated cash despite the loss, but with no positive earnings behind it, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
How financially healthy is BioLife Solutions Inc.?
BioLife Solutions Inc. (BLFS) scores 70 out of 100 on our Financial Health Score, indicating strong standing within its emerging companies peer group. The score is the average of six dimensions (Cash Runway, Dilution, R&D Intensity, Revenue Progress, Burn Trend, Balance Sheet), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.